Kesimpta pregnancy registry for pregnant people with MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This registry collects information about pregnancy outcomes in people with multiple sclerosis (MS) who have taken Kesimpta (ofatumumab) during pregnancy or shortly before it. It may help doctors better understand safety and developmental outcomes for babies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and were diagnosed with MS
- For the Kesimpta-exposed group: you took Kesimpta for MS during a specific time window around pregnancy
- You must agree to study interviews and allow sharing of medical records
- Your baby may be offered a specialized exam after birth (OTIS) and you may complete a child development questionnaire
- You cannot enroll if you previously joined this Kesimpta pregnancy study for an earlier pregnancy
- Your pregnancy must not have known major birth-structure defects before enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows pregnant people with multiple sclerosis (MS) who took Mayzent (siponimod) to understand safety for pregnancy outcomes. It compares them with other groups to see whether there are any differences in birth results.
This study is a pregnancy exposure registry. It collects information to better understand pregnancy outcomes after exposure to Stelara or Tremfya (medicines used for autoimmune diseases).
This study looks at the safety of Kesimpta (a multiple sclerosis medication) during pregnancy. It compares outcomes for women who took Kesimpta or other MS drugs while pregnant to those who did not.
This study compares how well two medicines, Kesimpta and Ocrevus, work for people with multiple sclerosis when used in real life. It looks at patient records to see which treatment might be more effective.
This trial looks at the safety of ozanimod taken during pregnancy for parents with multiple sclerosis and for their babies after birth. It may help doctors understand the risks and benefits of this medicine during early pregnancy.
This study collects information about pregnancies in people with multiple sclerosis (MS) who were exposed to Vumerity (diroximel fumarate) or who were not on MS medicines during pregnancy. It helps researchers understand pregnancy outcomes and safety in these situations.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.